ExonHit Therapeutics – Trademark Portfolio

Entity Type: 99

ExonHit Therapeutics holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 3 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 5 Nice Classification classes.

26, rue Brunel

F-75017 Paris

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

ExonHit Therapeutics's trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (3 filings)

Scientific and technological services; industrial analysis and research services

5
Pharmaceuticals (3 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

1
Chemicals (2 filings)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

10
Medical Apparatus (2 filings)

Surgical, medical, dental and veterinary apparatus and instruments

44
Medical Services (2 filings)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

Frequently Asked Questions

How many trademarks does ExonHit Therapeutics have?

ExonHit Therapeutics has 3 U.S. trademarks filed with the USPTO.

What trademark classes does ExonHit Therapeutics file in?

ExonHit Therapeutics files trademarks across 5 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 10 (Medical Apparatus), Class 44 (Medical Services). Class 42 covers scientific and technological services; industrial analysis and research services.

What is ExonHit Therapeutics's trademark registration success rate?

ExonHit Therapeutics has a 0% trademark registration rate, with 0 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.